Basics Sarepta Therapeutics, Inc. Sarepta Therapeutics Inc is a biotechnology company. It uses proprietary RNA-targeted technology platforms for developing pharmaceutical products to address serious diseases. IPO Date: July 12, 2012 Sector: Healthcare Industry: Biotech Market Cap: $2.44B Activated in VL: True Average Daily Range Avg Daily Range: $1.54 | 2.44% Avg Daily Range (30 D): $0.56 | 2.86% Avg Daily Range (90 D): $0.64 | 3.52% Institutional Daily Volume Avg Daily Volume: 1.79M Avg Daily Volume (30 D): 5.22M Avg Daily Volume (90 D): 9.7M Trade Size Avg Trade Size (Sh.): 107 Avg Trade Size (Sh.) (30 D): 105 Avg Trade Size (Sh.) (90 D): 121 Institutional Trades Total Inst.Trades: 13,582 Avg Inst. Trade: $4.05M Avg Inst. Trade (30 D): $3.26M Avg Inst. Trade (90 D): $3.25M Avg Inst. Trade Volume: .05M Avg Inst. Trades (Per Day): 4 Market Closing Trades Avg Closing Trade: $8.78M Avg Closing Trade (30 D): $8.27M Avg Closing Trade (90 D): $12.57M Avg Closing Volume: 115.86K     News Oct 7, 2025 @ 3:00 PM AAV Gene Therapy Market Size to Skyrocket at 40.1%... Source: Towards Healthcare Sep 5, 2025 @ 1:30 PM 2 Beaten-Down Stocks to Avoid Right Now Source: Prosper Junior Bakiny Aug 29, 2025 @ 7:13 PM SRPT Stock Alert: Investors with Large Losses Shou... Source: Robbins Llp Aug 28, 2025 @ 3:00 PM Genetic Material Market Size, Trends and Top Compa... Source: Towards Healthcare Aug 25, 2025 @ 7:10 AM SRPT Investors Have Opportunity to Lead Sarepta Th... Source: Prnewswire Financials   TTM Q2 2025 Q1 2025 Basic EPS $-.57 $2.01 $-4.6 Diluted EPS $-.81 $1.89 $-4.6 Revenue $ 2.48B $ 611.09M $ 744.86M Gross Profit $ $ $ Net Income / Loss $ -57.96M $ 196.89M $ -447.51M Operating Income / Loss $ -.93M $ 115.58M $ -300.39M Cost of Revenue $ $ $ Net Cash Flow $ 126.98M $ 269.73M $ -862.14M PE Ratio     Splits Jul 12, 2012:   1:6